21:45 , May 12, 2017 |  BioCentury  |  Strategy

Vertical vision

Shire plc ’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to...
18:50 , May 1, 2017 |  BC Extra  |  Company News

Shire, Parion in deal for ENaC inhibitor for dry eye

Parion Sciences Inc. (Durham, N.C.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to P-321 ophthalmic solution , an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease. Parion received $20 million...
14:57 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Zebrafish studies suggest inhibiting TGFβ1 or LFA-1 could help treat metastatic breast cancer. In patient samples, levels of TGFβ1 were higher in primary tumors than in surrounding normal tissue. In two xenograft...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Shire sales and marketing update

Shire launched Xiidra lifitegrast in the U.S. to treat signs and symptoms of dry eye disease in adults. The wholesale acquisition cost (WAC) of a 60-drop container is $426.73. Patients receive one drop of the...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Xiidra lifitegrast regulatory update

FDA approved an NDA from Shire for Xiidra lifitegrast to treat signs and symptoms of dry eye disease in adults. Shire plans to launch the product this quarter. Xiidra is an eye drop formulation of...
01:01 , Jul 12, 2016 |  BC Extra  |  Company News

FDA approves Shire's Xiidra

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA approved Xiidra lifitegrast ( SHP606 ) to treat signs and symptoms of dry eye disease in adults. The company expects to launch Xiidra this quarter. Shire obtained Xiidra via...
08:00 , Feb 25, 2016 |  BC Innovations  |  Product R&D

Ironwood's brainy idea

Selina Koch, Staff Writer  Ironwood Pharmaceuticals Inc. is pushing the scope of what its soluble guanylate cyclase (sGC) platform can do, with a new preclinical program to make brain-penetrating compounds that could move the company...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Lifitegrast regulatory update

Shire said FDA accepted a resubmitted NDA for lifitegrast to treat signs and symptoms of dry eye disease in adults. The PDUFA date is July 22. Last October, the company received a complete response letter...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Lifitegrast regulatory update

Shire resubmitted an NDA to FDA for lifitegrast to treat signs and symptoms of dry eye disease in adults. In October, the company received a complete response letter from FDA requesting an additional clinical study...
02:14 , Jan 26, 2016 |  BC Extra  |  Company News

Shire resubmits lifitegrast NDA

Shire plc (LSE:SHP; NASDAQ:SHPG) resubmitted an NDA to FDA for lifitegrast ( SHP606 ) to treat signs and symptoms of dry eye. The company had received a complete response letter from FDA in October requesting...